Ana Stok

Ana Stok

Auto-generated profile, based on publicly available information

Ana Stok

Centro de Investigaciones en Patologías Respiratorias, San Miguel de Tucumán, Argentina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2025 in Respirar
Verified
Journal Article
Open access
PDF file
IZIgnacio Zabert
Ignacio Zabert
ASAna María Stok
Ana María Stok
CCCarmen Cano
Carmen Cano
PFPatricia Fernández
Patricia Fernández
MMMaria Felicia Montero-Arias
Maria Felicia Montero-Arias
GGGabriel García
Gabriel García
Asthma affects millions of people around the world, including Latin America. Severe asthma is often underdiagnosed, with difficulty in both access to appropriate treatment and access to quality health services and there is a low level of education on its management; this has a significant impact on morbidity and mortality and quality of life of patients. In the year 2020 we elaborated the ALAT Severe Asthma GUIDE, considering the need to update and develop new recommendations, we present this document based on the best available evidence to the year 2024. In this new Guideline 2024, the recommendations have been based on the best available evidence and have been agreed upon by a group of experts representing most of the Latin American medical societies that are members of ALAT. The modified Delphi panel was used to achieve an appropriate level of consensus for each of the recommendations included in this CPG. Six new topics were included, such as the role of inhaled triple therapy in the definition of severe asthma, the new concepts of asthma remission and treatment failure, the identification of risk factors for exacerbations, the efficacy and safety of biologics in the treatment of adults with severe corticosteroid-dependent asthma and, finally, the efficacy and safety of anti-TSLP antibodies (tezepelumab). A specific guideline for the management of severe asthma is essential to improve diagnosis, standardize treatments, reduce inequalities in care and strengthen health systems by making more efficient use of available resources.

1 December 2025 in Respirar
Verified
Journal Article
Open access
PDF file
ASAna Stok
Ana Stok
FAFrancisco Javier Alvarez-gutierrez
Francisco Javier Alvarez-gutierrez
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
FCFrancisco Casas-Maldonado
Francisco Casas-Maldonado
CCCarmen Cano
Carmen Cano
JCJosé Gregorio Soto Campos
José Gregorio Soto Campos
Asthma exacerbation is a significant clinical event that occurs with varying severity, yet a set of universally accepted standardized definitions is still needed. The aim of this consensus developed by ALAT and SEPAR was to fill this gap with a validated proposal for classifying asthma exacerbations into levels of severity: non-severe, severe, and very severe. The consensus was based on an in-depth review of the literature conducted by the scientific committee to identify key parameters for each level of severity, including worsening symptoms, respiratory function changes, and the need for specific medical interventions. A total of 67 publications were analyzed to generate a questionnaire on the defining elements of asthma exacerbations, and this was put to the vote. Twenty-eight international experts participated in the validation of characteristics and definitions of exacerbation severity following Delphi methodology. The resulting definitions clearly distinguish non-severe exacerbations (requiring minor adjustments in treatment) from severe exacerbations (requiring more intensive interventions, including longer systemic corticosteroid use or hospitalization) and very severe exacerbations (life-threatening events requiring intensive care). These definitions provide a standardized framework that facilitates comparison between clinical trials and optimizes patient care. This consensus lays the foundation for unifying management criteria in global clinical practice and fostering research on the efficacy of asthma treatments. It also underlines the importance of accurate classification in improving clinical outcomes and reducing the overall burden of disease.

1 September 2026 in Respirar
Verified
Journal Article
Open access
PDF file
ASAna Stok
Ana Stok
MCM. del Carmen Cano-Salas
M. del Carmen Cano-Salas
GGGabriel García
Gabriel García
PFPatricia Fernández-Vasquez
Patricia Fernández-Vasquez
MAMiguel Antúnez-Rivero
Miguel Antúnez-Rivero
MCM. Cecilia Cavallo
M. Cecilia Cavallo
Introducción: Los corticosteroides sistémicos han sido durante más de siete décadas una herramienta fundamental en el tratamiento de enfermedades inflamatorias crónicas, en particular el asma. Sin embargo, su uso extendido e indiscriminado genera creciente preocupación por su asociación con múltiples efectos adversos sistémicos y su impacto clínico y económico. Objetivo: Analizar críticamente la evidencia sobre los patrones de uso de corticosteroides sistémicos, su perfil de seguridad y su impacto clínico y económico, con especial énfasis en el asma, y establecer recomendaciones para un uso más racional y seguro. Métodos: Documento de posición del Departamento de Asma de la Asociación Latinoamericana de Tórax (ALAT), basado en una revisión narrativa de la literatura y en el consenso de expertos. Resultados: La prevalencia de uso es elevada a nivel global, especialmente en pacientes con asma y otras enfermedades respiratorias crónicas. Incluso exposiciones breves o dosis acumuladas bajas aumentan el riesgo de efectos adversos graves —infecciones, eventos cardiovasculares, osteoporosis, alteraciones metabólicas y supresión del eje hipotálamo-hipófiso-adrenal—, con mayor morbimortalidad y costos. En asma grave, la evidencia reciente impulsa un cambio de paradigma orientado a minimizar la exposición mediante el uso racional, la optimización del tratamiento de base y las terapias biológicas dirigidas. Conclusiones: Los corticosteroides sistémicos son indispensables, pero su uso excesivo o inapropiado genera una importante carga clínica y económica. El uso racional, la monitorización activa de efectos adversos y la adopción temprana de terapias ahorradoras de esteroides son estrategias clave para mejorar la seguridad del tratamiento, particularmente en el asma grave.

1 December 2025 in Respirar
Verified
Journal Article
Open access
PDF file
IZIgnacio Zabert
Ignacio Zabert
ASAna Stok
Ana Stok
MCMaria del Carmen Cano
Maria del Carmen Cano
MMMaria Felicia Montero-Arias
Maria Felicia Montero-Arias
AAAbram Ali
Abram Ali
GGGabriel Garcia
Gabriel Garcia
Introduction: Severe asthma (SA) affects 5-15% of asthmatic patients, carrying a high clinical and economic burden. Heterogeneity exists in its presentation and management, with limited information in Latin America. The ALAT's Latin American Severe Asthma Registry (REAL) was designed to characterize this population in the region. Primary objective: To describe the natural history and the clinical, functional, phenotypic, and therapeutic characteristics of patients with SA in Latin America. Methods: Observational, prospective, multicenter study in specialized centers across Latin America. Patients ≥ 18 years old diagnosed with SA according to ALAT/ERS/ATS criteria, providing informed consent, were included. Three visits (baseline, 6, and 12 months) recorded demographic, clinical (symptom control via ACT, exacerbations, systemic corticosteroids, hospitalizations), functional (spirometry), biomarker (eosinophils, IgE, prick test, FeNO if available), comorbidity, treatment (including biologics), and adherence (TAI) variables. Data will be managed using REDCap. Descriptive and comparative analyses will be performed; prognostic factors will be explored using regression models. Ethical Considerations: The protocol requires approval from each participating center's Ethics Committee. Written informed consent will be obtained. Data confidentiality will be ensured. Discussion/Expected Outcomes: The REAL Registry will generate specific information on SA in Latin America, allowing the identification of prevalent phenotypes and the evaluation of real-world treatment patterns (to assess the response in the subgroup of patients treated with biologics) and clinical outcomes. This will contribute to optimizing management, guiding public health strategies and fostering research adapted to the region.